LifeMD Statistics
Total Valuation
LifeMD has a market cap or net worth of $271.51 million. The enterprise value is $256.71 million.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LifeMD has 44.58 million shares outstanding. The number of shares has increased by 21.51% in one year.
| Current Share Class | 44.58M |
| Shares Outstanding | 44.58M |
| Shares Change (YoY) | +21.51% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 16.08% |
| Owned by Institutions (%) | 36.74% |
| Float | 35.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.18 |
| Forward PS | 0.99 |
| PB Ratio | -65.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.64 |
| P/OCF Ratio | 15.22 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 16.02 |
Financial Position
The company has a current ratio of 0.81
| Current Ratio | 0.81 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.57 |
| Interest Coverage | -7.40 |
Financial Efficiency
Return on equity (ROE) is -2,463.00% and return on invested capital (ROIC) is -44.30%.
| Return on Equity (ROE) | -2,463.00% |
| Return on Assets (ROA) | -15.41% |
| Return on Invested Capital (ROIC) | -44.30% |
| Return on Capital Employed (ROCE) | -132.28% |
| Revenue Per Employee | $692,032 |
| Profits Per Employee | -$71,622 |
| Employee Count | 307 |
| Asset Turnover | 3.25 |
| Inventory Turnover | 8.66 |
Taxes
In the past 12 months, LifeMD has paid $402,000 in taxes.
| Income Tax | 402,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.43% in the last 52 weeks. The beta is 2.22, so LifeMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.22 |
| 52-Week Price Change | -45.43% |
| 50-Day Moving Average | 5.62 |
| 200-Day Moving Average | 5.51 |
| Relative Strength Index (RSI) | 62.23 |
| Average Volume (20 Days) | 673,282 |
Short Selling Information
The latest short interest is 7.41 million, so 16.63% of the outstanding shares have been sold short.
| Short Interest | 7.41M |
| Short Previous Month | 8.16M |
| Short % of Shares Out | 16.63% |
| Short % of Float | 20.76% |
| Short Ratio (days to cover) | 4.71 |
Income Statement
In the last 12 months, LifeMD had revenue of $212.45 million and -$21.99 million in losses. Loss per share was -$0.53.
| Revenue | 212.45M |
| Gross Profit | 188.39M |
| Operating Income | -16.14M |
| Pretax Income | -23.07M |
| Net Income | -21.99M |
| EBITDA | -14.67M |
| EBIT | -16.14M |
| Loss Per Share | -$0.53 |
Full Income StatementBalance Sheet
The company has $35.00 million in cash and $25.10 million in debt, giving a net cash position of $9.90 million or $0.22 per share.
| Cash & Cash Equivalents | 35.00M |
| Total Debt | 25.10M |
| Net Cash | 9.90M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | -4.05M |
| Book Value Per Share | -0.13 |
| Working Capital | -11.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $17.51 million and capital expenditures -$1.49 million, giving a free cash flow of $16.02 million.
| Operating Cash Flow | 17.51M |
| Capital Expenditures | -1.49M |
| Free Cash Flow | 16.02M |
| FCF Per Share | $0.36 |
Full Cash Flow StatementMargins
Gross margin is 88.67%, with operating and profit margins of -7.60% and -8.89%.
| Gross Margin | 88.67% |
| Operating Margin | -7.60% |
| Pretax Margin | -8.63% |
| Profit Margin | -8.89% |
| EBITDA Margin | -6.91% |
| EBIT Margin | -7.60% |
| FCF Margin | 7.54% |
Dividends & Yields
LifeMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.51% |
| Shareholder Yield | -21.51% |
| Earnings Yield | -8.25% |
| FCF Yield | 6.01% |
Analyst Forecast
The average price target for LifeMD is $11.17, which is 83.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.17 |
| Price Target Difference | 83.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on October 14, 2020. It was a reverse split with a ratio of 0.2:1.
| Last Split Date | Oct 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.2:1 |
Scores
LifeMD has an Altman Z-Score of -0.32 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.32 |
| Piotroski F-Score | 4 |